WorldCare Clinical, LLC (WCC) introduced a new service offering that supports expert readers in a timely and transparent manner to complete cardiovascular endpoint committee reviews quickly and cost-effectively.
In response to FDA guidance and growing requests from other regulatory agencies that place new emphasis on assessing and minimizing cardiovascular risk, WCC has developed a comprehensive and easy-to-use solution for cost-effective, Blinded Independent Central Review (BICR) of adverse events (AEs) using the Medical Dictionary for Regulatory Activities (MedDRA) and other safety coding dictionaries. WCC’s new service offering builds upon the company’s extensive Endpoint Assessment Committee (EAC) services and employs its WorldPRO® image management platform to capture, quantify and consolidate virtually any type of clinical data for interpretation by sub-specialty trained experts.
"We’re excited to introduce the first of several new services we’ll be offering to sponsors in the coming months," said Richard Walovitch, PhD, president of WorldCare Clinical, LLC. "Through our long-standing strategic relationship with Massachusetts General Hospital (MGH), we’re able to deliver the most accurate assessments by providing access to leading clinical experts to meet each trial’s specific protocol requirements. This combined with our proprietary digital portal, WorldPRO, provides the ability to streamline the BICR process and highlights the flexibility of our capabilities."
WCC’s new service offering for cardiovascular endpoint committees consists of the following:
The WorldPRO system can be accessed by multiple clinical scientists at different locations to collate potential Events of Interest (EoIs) for internal or external review. Equipped with a smart work queue and automated adjudication workflow, WorldPRO allows clinicians to review data efficiently to further expedite the review process. Additionally, WCC has included a standardized scoring system to assess the degree of certainty of the EoI. This unique feature enables WCC to better determine variance in AE coding between independent reviews, while maintaining training and testing programs that maximize the precision and accuracy of a clinical trial.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.